Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
5,220 people get NVS articles and Market Currents by email alert.
Get email alerts on NVS »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
Novartis Moving Forward In GenericsPeter Pham • Mon, Dec 3, 2012 -
-
AHA - 2 Hits And Several Misses With Novartis' SerelaxinEP Vantage • Wed, Nov 7, 2012 -
-
-
-
-
-
-
-
-
-
Novartis AG's CEO Discusses Q1 2012 Results - Earnings Call TranscriptTue, Apr 24, 2012 • 1 Comment
-
Novartis AG's CEO Discusses Q4 2011 Results - Earnings Call TranscriptWed, Jan 25, 2012
-
Novartis AG's CEO Discusses Q3 2011 Results - Earnings Call TranscriptTue, Oct 25, 2011
-
Novartis AG's CEO Discusses Q2 2011 Results - Earnings Call TranscriptTue, Jul 19, 2011
-
Novartis CEO Discusses Q4 2010 Results - Earnings Call TranscriptThu, Jan 27, 2011
-
Novartis 2009 Annual Conference Call TranscriptTue, Jan 26, 2010
-
Novartis AG Q3 2007 Earnings Call TranscriptThu, Oct 18, 2007 • 1 Comment
-
Novartis Q2 2007 Earnings Call TranscriptTue, Jul 17, 2007
-
at CNBC.com (May 16, 2013)
-
at CNBC.com (May 15, 2013)
-
at CNBC.com (May 10, 2013)
-
at Fox Business (Apr 26, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at MarketWatch.com (Apr 16, 2013)
-
at MarketWatch.com (Apr 15, 2013)
-
at CNBC.com (Apr 8, 2013)
-
at CNBC.com (Apr 3, 2013)
-
at MarketWatch.com (Apr 1, 2013)
-
at MarketWatch.com (Apr 1, 2013)
-
at Fox Business (Apr 1, 2013)
-
at MarketWatch.com (Apr 1, 2013)
-
at CNBC.com (Apr 1, 2013)
-
at CNBC.com (Apr 1, 2013)
-
at MarketWatch.com (Apr 1, 2013)
-
at CNBC.com (Feb 19, 2013)
-
at CNBC.com (Feb 1, 2013)
NVS vs. ETF Alternatives
Company Description
Currently, there's no company description for NVS.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, March 4, 2:42 AM As expected, Swiss voters have approved an "anti-fat cat" initiative that allows investors to hold binding votes every year on executive pay at listed companies, and enable them to block large payouts at the start and end of a manager's employment. Executives who break the new law could face hefty fines and up to three years in jail. 5 Comments [Global & FX, Top Stories]
- Sunday, March 3, 3:47 AM The Swiss are voting in a referendum today on an "anti-fat cat" initiative that would allow investors to hold binding votes on executive pay at listed companies and allow them to block large payouts at the start or end of a manager's employment. The measure is expected to pass. Companies that will be affected include Novartis (NVS), Nestle, UBS, Credit Suisse (CS), ABB, Roche, Transocean (RIG) and Weatherford (WFT). 13 Comments [Financials, Healthcare, Consumer, Top Stories]
- Tuesday, February 19, 7:31 AM Amid an uproar from shareholders, Novartis (NVS) cancels a plan to pay outgoing Chairman Daniel Vasella $78M. The cancellation also eliminates the noncompete agreement, leaving Dr. Vasella free to work where he chooses. 1 Comment [Healthcare]
- Sunday, February 17, 4:55 AM Novartis (NVS) Chairman Daniel Vasella will receive a six-year severance package of up to 72M Swiss francs ($78M) when he leaves the pharmaceutical company this month, as long as he doesn't start working for rivals. The agreement has further ignited strong feelings in Switzerland ahead of a March referendum over giving shareholders a say over executive compensation. 2 Comments [Healthcare]
- Thursday, January 31, 9:33 AM EU antitrust regulators send Johnson & Johnson (JNJ -0.1%) and Novartis (NVS -0.3%) a "statement of objections," or charge sheet, over a "co-promotion" deal they formulated that delayed the release of a generic competitor to J&J's painkiller fentanyl in Holland for 17 months in 2005-2006. The EU can levy fines of up to 10% of annual sales for anti-competitive behavior, although penalties are usually based on the revenues of the product involved. (PR) Comment! [Healthcare]
- Wednesday, January 23, 11:11 AM Citigroup likes what it sees in Novartis' (NVS +3.6%) today, upgrading the European drug giant to Buy on the back of a solid quarter and significant management changes. Citi says the departure of Dr. Vasella could lead to shareholder friendly activity, including; a streamlining of the company's group structure, monetization of its Roche (RHHBY.PK stake and a possible re-initiation of its buyback program. Comment! [Healthcare, On the Move]
- Wednesday, January 23, 4:06 AM More on Novartis (NVS) Q4: Chairman Daniel Vasella will resign and will be replaced by senior Bayer health-care executive Joerg Reinhardt, who was formerly COO at Novartis. Provides mid-term guidance for the first time, forecasting mid-single-digit percentage fall in core earnings this year; sales to be in line with 2012, excluding currency swings, although generic competition will eat into revenue by up to $3.5B. Sales growth to resume in 2014 and 2015. Comment! [Earnings, Healthcare]
- Wednesday, January 23, 4:04 AM More on Novartis (NVS) Q4: Adjusted profit +3% to $3.1B. Net profit +74% to $2.05B, below consensus of $2.38B. Last year was affected by writedowns. Pharmaceutical division sales flat at $8.3B, Diovan sales -25% to $992M after loss of patent protection. Shares +2.4% in Zurich. Comment! [Earnings, Healthcare]
- Wednesday, January 23, 3:42 AM Novartis AG (NVS): Q4 EPS of $1.27 may not be comparable to consensus of $1.31. Revenue of $14.8B (flat% Y/Y). The board intends to declare annual dividend of CHF2.25/share, 2.0% increase from prior dividend of CHF2.30. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Wednesday, January 23, 12:05 AM Notable earnings before Wednesday’s open: ABBV, ABT, APD, ATI, BHI, CHKP, COH, DGX, FNFG, GD, LCC, MCD, MSI, NVS, PX, RES, SAP, STJ, TEL, TXT, UTX, WLP Comment! [Earnings]
- Tuesday, January 22, 5:30 PM Notable earnings before Wednesday’s open: ABBV, ABT, APD, ATI, BHI, CHKP, COH, DGX, FNFG, GD, LCC, MCD, MSI, NVS, PX, RES, SAP, STJ, TEL, TXT, UTX, WLP Comment! [Earnings]
- Tuesday, January 15, 6:08 AM Looking to offset a patent cliff that could cut sales by up to $2.75B this year, Pfizer (PFE) is among the companies reportedly interested in acquiring Agila Specialties, the injectable-medicines unit of India's Strides Arcolab. Novartis (NVS), Mylan (MYL) and Fresenius (APCVZ) have also been eyeing Agila, which produces cancer treatments and antibiotics, and could be valued at $2B. Comment! [Healthcare, M&A]
- Tuesday, January 8, 8:54 AM Novartis (NVS) CEO Joe Jimenez says the company may make bolt-on purchases of $2-4B but doesn't "need a big acquisition in the short term." Novartis is looking to buy assets to offset patent expirations, with Jimenez saying the firm wants to expand its generics business with respiratory and dermatology treatments, and injectable cancer therapies. The company won't sell its loss-making vaccines ops or other smaller units. Comment! [Healthcare]
- Wednesday, January 2, 9:32 AM "The (pharmaceutical) industry needs to spend more money on R&D and less on sales and marketing, says Novartis (NVS +1.2%) CEO Joseph Jimenez. He also believes "that in the future, companies like Novartis are going to be paid on patient outcomes as opposed to selling the pill." However, Jimenez warns that price cuts, such as those in Europe, "create a disincentive for us to build sales force." Comment! [Healthcare]
- Thursday, December 27, 2012, 3:45 PM A federal judge has ruled in favor of the FDA and dismissed Mylan's (MYL -0.5%) suit against the agency relating to it's decision to withhold approval for the company to sell a generic version of Novartis' (NVS +0.4%) heart drug Diovan. The court said the FDA had not acted “capriciously” when it denied MYL exclusivity to market its version, furthermore, the company failed to show it suffered “irreparable harm” as a result, Comment! [Healthcare]
- Thursday, December 20, 2012, 11:02 AM Trovagene (TROV +8%) gets a pop today after granting Novartis (NVS) subsidiary Genoptix licensing rights to incorporate its nucleophosmin protein, NPM1, into research and clinical testing services for acute myelogenous leukemia. Trovagene holds an exclusive patent on the protein. Terms of the agreement include upfront fees and royalty payments. Additional financial terms were not disclosed. Additionally, Roth Capital initiates the shares with a Buy and a price target of $11 a share. Comment! [Healthcare, On the Move]
-
- View all 0 replies
-
Ryan Mallory
16 Defensive Stock Plays to Weather Market Uncertainty http://bit.ly/RVR8Ko AAPL ABT AMZN AZN MRK NVS PEP to name a few of them - View all 1 replies
-
driftking27: How do you see the strong CHf affecting there growth. I think that could be one hurdle that could hurt there sales. Plus NVS drops more...
-
Joe Springer
#biotech #pharma #stocks $VNDA $LLY $PPHM $GHDX $SCLN $AMRN $CRTX $NVS Vanda looks like a buy here: http://seekingalpha.com/a/h3pb - View all 0 replies
-
Jacob Wolinsky
Johnson & Johnson: Why Value Investors Should be Looking http://bit.ly/M6zDRh $JNJ $NVS $AZN $BMY $PFE $GS - View all 1 replies
-
-
- View all 0 replies
-
- View all 2 replies
-
-
Caiman Valores: YPF won't be paying a dividend, likely to be nationalized by Argentine government, find out more in my article http://bit.ly/ICs5GM
-
- View all 4 replies
-
shvartz: I bought at about 57. Adding the div to today's price gets about 58. And that is without tax, so for me there very little gain. -
Ocean Man: I bought some at 54.80 and sold at 57.40 pre-div, and I bought some at 55.80 which I sold today.
-
The Scientist
Still waiting for a response from AF from The Street on the licensing deals by APRI with ABT and NVS. Shows the value of NexACT technology - View all 1 replies
-
The Scientist: Huge multi-national biotechs do not do licensing deals with microcap biotech's unless they felt the technology is novel.
-
- View all 1 replies
-
-
- View all 3 replies
-
briandiplacido: Marked my shares up a buck @ 57.74 and someone took it premarket. Look for better re-entry now.
-
LATEST REPLIES
-
- View all 1 replies
-
-
- View all 3 replies
-
-
-
- View all 14 replies
-
-
-
- View all 1 replies
-
-
- View all 3 replies
-
Ocean Man: Canadian but do most of their business in the US. Doubled their size a few months ago with an acquisition, said was immediately accretive.
-
neobliviscar: Heck of a yield. Need to sic our balance sheet terrier on it as soon as I can get her to look at it. I wish options mrkt on it was bigger.